The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy.
Treatment of hemophilia, although greatly improved in recent years, continues to be problematic owing to infectious complications of blood product replacement therapy. This report examines the therapeutic options presently available for the treatment of hemophilia, focusing on the potential for repeated viral exposure to influence the progression of infectious disease, decreased risks of viral transmission with blood products produced using newer viral inactivation procedures, higher economic costs of newer blood products, and the current inadequate supply of blood products in the United States.
Pierce
G F
GF
Department of Pathology, Washington University Medical Center, St Louis, Mo.
Lusher
J M
JM
Brownstein
A P
AP
Goldsmith
J C
JC
Kessler
C M
CM
D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control / Q000635:transmission*; D003257:Consumer Product Safety; D003365:Costs and Cost Analysis; D004340:Drug Contamination; D005164:Factor IX / Q000008:administration & dosage* / Q000009:adverse effects / Q000600:supply & distribution; D005169:Factor VIII / Q000008:administration & dosage* / Q000009:adverse effects / Q000600:supply & distribution; D006467:Hemophilia A / Q000628:therapy*; D006525:Hepatitis, Viral, Human / Q000517:prevention & control / Q000635:transmission*; D006801:Humans
D005169:Factor VIII; D005164:Factor IX